ArticleFrontiers in pharmacology2020
Constituents and Metabolites of a French Oak Wood Extract (Robuvit
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- The Oak-wood Extract RobuvitNutrients · 2020Trial
- The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy.Molecular biology reports · 2026Review
- Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review.Frontiers in nutrition · 2026Review
- Potential Use ofPharmaceutics · 2023Article
- Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota.Molecular nutrition & food research · 2022Review
- Review of Clinical Effects and Presumed Mechanism of Action of the French Oak Wood Extract Robuvit.Journal of medicinal food · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ellagitannins are signature constituents of oak wood and their consumption has been associated with various health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.